Cargando…
The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level
Inactivating mutations in ARID1A, which encodes a subunit of the SWI/SNF chromatin-remodeling complex, are found in over half of ovarian clear cell carcinoma cases and more broadly across most types of cancers. To identify ARID1A-dependent changes in intracellular signaling pathways, we performed pr...
Autores principales: | Goldman, Aaron R., Bitler, Benjamin G., Schug, Zachary, Conejo-Garcia, Jose R., Zhang, Rugang, Speicher, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098034/ https://www.ncbi.nlm.nih.gov/pubmed/27654507 http://dx.doi.org/10.1074/mcp.M116.062539 |
Ejemplares similares
-
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
por: Fukumoto, Takeshi, et al.
Publicado: (2018) -
ARID1A-mutated ovarian cancers depend on HDAC6 activity
por: Bitler, Benjamin G., et al.
Publicado: (2017) -
CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer
por: Singha, Bipradeb, et al.
Publicado: (2018) -
SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
por: Wu, Shuai, et al.
Publicado: (2018) -
Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal
por: Biter, Benjamin G., et al.
Publicado: (2015)